HUP0402067A2 - Oltóanyagok - Google Patents

Oltóanyagok

Info

Publication number
HUP0402067A2
HUP0402067A2 HU0402067A HUP0402067A HUP0402067A2 HU P0402067 A2 HUP0402067 A2 HU P0402067A2 HU 0402067 A HU0402067 A HU 0402067A HU P0402067 A HUP0402067 A HU P0402067A HU P0402067 A2 HUP0402067 A2 HU P0402067A2
Authority
HU
Hungary
Prior art keywords
antigen
saponin
subject
preparation
combination
Prior art date
Application number
HU0402067A
Other languages
English (en)
Inventor
Nathalie Garcon
Catherine Marie Ghislaine Gerard
Jean Stephenne
Original Assignee
Glaxosmithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0025574A external-priority patent/GB0025574D0/en
Priority claimed from US09/690,921 external-priority patent/US6544518B1/en
Priority claimed from GB0025573A external-priority patent/GB0025573D0/en
Application filed by Glaxosmithkline Beecham Biologicals S.A. filed Critical Glaxosmithkline Beecham Biologicals S.A.
Publication of HUP0402067A2 publication Critical patent/HUP0402067A2/hu
Publication of HUP0402067A3 publication Critical patent/HUP0402067A3/hu
Publication of HU229642B1 publication Critical patent/HU229642B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány tárgyát képezi új készítmény, amely rákantigén vagy annakegy származéka, valamint egy immunstimuláns oligonukleotidot és egyszaponint tartalmazó kombinált adjuvánskészítmény kombinációjáttartalmazza. A találmány egy előnyös megvalósítási módjában azadjuvánskészítmény tartalmaz még egy lipopoliszacharidot is. Azantigén előnyösen egy Her2/Neu-származék vagy egy prosztataantigén. Atalálmány tárgyát képezik szaponin, immunstimuláns oligonukleotid ésaz antigének közül legalább egyetlen kombinációjának alkalmazása,továbbá eljárások gyógyászati készítmények előállítására. A találmányszerinti készítmények alkalmazhatók különböző antigéneket expresszálóemberek kezelésére és megelőző kezelésére. Ó
HU0402067A 2000-10-18 2001-10-16 Vaccines against cancers HU229642B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0025574A GB0025574D0 (en) 2000-10-18 2000-10-18 Vaccine
US09/690,921 US6544518B1 (en) 1999-04-19 2000-10-18 Vaccines
GB0025573A GB0025573D0 (en) 2000-10-18 2000-10-18 Vaccine
PCT/EP2001/011984 WO2002032450A2 (en) 2000-10-18 2001-10-16 Vaccines

Publications (3)

Publication Number Publication Date
HUP0402067A2 true HUP0402067A2 (hu) 2005-01-28
HUP0402067A3 HUP0402067A3 (en) 2012-09-28
HU229642B1 HU229642B1 (en) 2014-03-28

Family

ID=27255945

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402067A HU229642B1 (en) 2000-10-18 2001-10-16 Vaccines against cancers

Country Status (18)

Country Link
EP (2) EP1326638B9 (hu)
JP (1) JP2004511527A (hu)
KR (1) KR100860893B1 (hu)
CN (1) CN100548373C (hu)
AU (2) AU2002244337B2 (hu)
BR (1) BR0114786A (hu)
CA (1) CA2425358C (hu)
CZ (1) CZ302449B6 (hu)
DK (1) DK1326638T3 (hu)
ES (1) ES2295229T3 (hu)
HU (1) HU229642B1 (hu)
IL (1) IL155282A0 (hu)
MX (1) MXPA03003408A (hu)
NO (1) NO335919B1 (hu)
NZ (1) NZ525320A (hu)
PL (1) PL208755B1 (hu)
SI (1) SI1326638T1 (hu)
WO (1) WO2002032450A2 (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69929444T2 (de) 1998-08-10 2006-09-28 Antigenics Inc., Woburn Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
NZ513935A (en) 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2471092A1 (en) 2001-12-21 2003-07-10 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
US20040005338A1 (en) * 2002-06-20 2004-01-08 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
JP2006501249A (ja) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
AU2004285561C1 (en) 2003-10-30 2012-06-21 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
EP2484374A1 (en) * 2004-07-18 2012-08-08 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US20080267963A1 (en) * 2004-11-02 2008-10-30 Biomedical Research Model, Inc. Methods of Cancer Treatment/Prevention Using Cancer Cell-Specific Surface Antigens
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DK2368572T3 (da) 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
US20110293700A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
EP2736537A4 (en) 2011-07-29 2015-04-15 Selecta Biosciences Inc SYNTHETIC NANOTRANSPORTERS FOR THE PRODUCTION OF HUMOROUS AND CYTOTOXIC T-LYMPHOCY (CTL) IMMUNE REACTIONS
AU2012301664A1 (en) * 2011-08-31 2014-02-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
CA2879066C (en) * 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
EA201590396A1 (ru) * 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
EP2777711A1 (en) * 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
MY175308A (en) 2013-05-18 2020-06-18 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
AU2014321369B2 (en) * 2013-09-19 2020-04-16 Zoetis Services Llc Oil-based adjuvants
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
SG10201912897UA (en) 2014-01-16 2020-02-27 Wave Life Sciences Ltd Chiral design

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69929310T2 (de) * 1998-02-05 2006-08-03 Glaxosmithkline Biologicals S.A. Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
IL139813A0 (en) * 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
DE69929444T2 (de) * 1998-08-10 2006-09-28 Antigenics Inc., Woburn Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
DE60044665D1 (de) * 1999-01-29 2010-08-26 Corixa Corp Her2/neu fusionsproteine
DE60014076T2 (de) * 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
WO2001051083A2 (en) * 2000-01-13 2001-07-19 Antigenics Inc. Innate immunity-stimulating compositions of cpg and saponin and methods thereof
EP1350262B8 (en) * 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-like nucleic acids and methods of use thereof

Also Published As

Publication number Publication date
CN1481255A (zh) 2004-03-10
WO2002032450A3 (en) 2002-10-10
JP2004511527A (ja) 2004-04-15
CA2425358A1 (en) 2002-04-25
EP1889630B1 (en) 2011-11-23
AU4433702A (en) 2002-04-29
WO2002032450A2 (en) 2002-04-25
NO20031705L (no) 2003-06-14
IL155282A0 (en) 2003-11-23
HUP0402067A3 (en) 2012-09-28
SI1326638T1 (sl) 2008-04-30
MXPA03003408A (es) 2005-06-30
PL208755B1 (pl) 2011-06-30
PL365598A1 (en) 2005-01-10
EP1889630A1 (en) 2008-02-20
EP1326638B1 (en) 2007-11-28
EP1326638B9 (en) 2008-02-20
CZ20031093A3 (cs) 2003-08-13
DK1326638T3 (da) 2008-03-25
NZ525320A (en) 2004-10-29
NO335919B1 (no) 2015-03-23
CA2425358C (en) 2012-08-21
HU229642B1 (en) 2014-03-28
KR100860893B1 (ko) 2008-09-29
KR20070114230A (ko) 2007-11-29
EP1326638A2 (en) 2003-07-16
ES2295229T3 (es) 2008-04-16
NO20031705D0 (no) 2003-04-11
CN100548373C (zh) 2009-10-14
AU2002244337B2 (en) 2005-08-11
BR0114786A (pt) 2003-08-12
CZ302449B6 (cs) 2011-05-25

Similar Documents

Publication Publication Date Title
HUP0402067A2 (hu) Oltóanyagok
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
NO20015073L (no) Vaksiner
HUP0301180A2 (hu) Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
HUP9801560A1 (hu) Szaponint és szterint tartalmazó vakcinák
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
MY129263A (en) Vaccine composition
HUP0202885A2 (hu) Oltóanyagok
GB0123580D0 (en) Vaccine
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
EP1568373A3 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
HUP0103085A1 (hu) Készítmények és eljárások poliszacharid elleni immunválasz kiváltására
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
HUP0203972A2 (hu) Antigént és glikolipidet tartalmazó készítmény szublingvális úton történő alkalmazásra
WO2002102299A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
HUP0303372A2 (hu) Vakcina
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
EP1660686A4 (en) EPITOPES OF CD8 + HPV T LYMPHOCYTES
HUP0204216A2 (en) A new use of antibodies as vaccines
WO2001070265A3 (en) Lipopeptide adjuvants
MY127452A (en) Vaccines.
HK1025220A1 (en) Novel saponin compositions and uses thereof
WO2002036160A3 (es) Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees